Search

Your search keyword '"Giske, Christian G."' showing total 841 results
Start Over Author "Giske, Christian G."
841 results on '"Giske, Christian G."'

2. Outcomes of octogenarians and nonagenarians with Pseudomonas aeruginosa bacteremia: a multicenter retrospective study

Author

Atamna, Alaa, Margalit, Ili, Ayada, Gida, Babich, Tanya, Naucler, Pontus, Valik, John Karlsson, Giske, Christian G., Benito, Natividad, Cardona, Ruben, Rivera, Alba, Pulcini, Celine, Fattah, Manal Abdel, Haquin, Justine, Macgowan, Alasdair, Chazan, Bibiana, Yanovskay, Anna, Ami, Ronen Ben, Landes, Michal, Nesher, Lior, Zaidman-Shimshovitz, Adi, McCarthy, Kate, Paterson, David L., Tacconelli, Evelina, Buhl, Michael, Mauer, Susanna, Rodríguez-Baño, Jesús, de Cueto, Marina, Oliver, Antonio, de Gopegui, Enrique Ruiz, Cano, Angela, Machuca, Isabel, Gozalo-Marguello, Monica, Martinez-Martinez, Luis, Gonzalez-Barbera, Eva M., Alfaro, Iris Gomez, Salavert, Miguel, Beovic, Bojana, Saje, Andreja, Mueller–Premru, Manica, Pagani, Leonardo, Vitrat, Virginie, Kofteridis, Diamantis, Zacharioudaki, Maria, Maraki, Sofia, Weissman, Yulia, Paul, Mical, Dickstei, Yaakov, and Yahav, Dafna

Published
2023
Full Text
View/download PDF

5. Pseudomonasaeruginosa antimicrobial susceptibility profiles, resistance mechanisms and international clonal lineages: update from ESGARS-ESCMID/ISARPAE Group

Author

Oliver, Antonio, Rojo-Molinero, Estrella, Arca-Suarez, Jorge, Beşli, Yeşim, Bogaerts, Pierre, Cantón, Rafael, Cimen, Cansu, Croughs, Peter D., Denis, Olivier, Giske, Christian G., Graells, Tíscar, Daniel Huang, Te-Din, Iorga, Bogdan I., Karatuna, Onur, Kocsis, Béla, Kronenberg, Andreas, López-Causapé, Carla, Malhotra-Kumar, Surbhi, Martínez, Luis Martínez, Mazzariol, Annarita, Meyer, Sylvain, Naas, Thierry, Notermans, Daan W., Oteo-Iglesias, Jesús, Pedersen, Torunn, Pirš, Mateja, Poeta, Patricia, Poirel, Laurent, Pournaras, Spyros, Sundsfjord, Arnfinn, Szabó, Dora, Tambić-Andrašević, Arjana, Vatcheva-Dobrevska, Rossitza, Vitkauskienė, Astra, and Jeannot, Katy

Published
2024
Full Text
View/download PDF

8. Towards clinical breakpoints for non-tuberculous mycobacteria – Determination of epidemiological cut off values for the Mycobacterium avium complex and Mycobacterium abscessus using broth microdilution

Author

Fröberg, Gabrielle, Maurer, Florian P., Chryssanthou, Erja, Fernström, Louise, Benmansour, Hanaa, Boarbi, Samira, Mengshoel, Anne Torunn, Keller, Peter Michael, Viveiros, Miguel, Machado, Diana, Fitzgibbon, Margaret M., Mok, Simone, Werngren, Jim, Cirillo, Daniela Maria, Alcaide, Fernando, Hyyryläinen, Hanne-Leena, Aubry, Alexandra, Andres, Sönke, Nadarajan, Darshaalini, Svensson, Erik, Turnidge, John, Giske, Christian G., Kahlmeter, Gunnar, Cambau, Emmanuelle, van Ingen, Jakko, and Schön, Thomas

Published
2023
Full Text
View/download PDF

9. Duration of Treatment for Pseudomonas aeruginosa Bacteremia: a Retrospective Study

Author

Babich, Tanya, Naucler, Pontus, Valik, John Karlsson, Giske, Christian G., Benito, Natividad, Cardona, Ruben, Rivera, Alba, Pulcini, Celine, Fattah, Manal Abdel, Haquin, Justine, Macgowan, Alasdair, Grier, Sally, Chazan, Bibiana, Yanovskay, Anna, Ami, Ronen Ben, Landes, Michal, Nesher, Lior, Zaidman-Shimshovitz, Adi, McCarthy, Kate, Paterson, David L., Tacconelli, Evelina, Buhl, Michael, Mauer, Susanna, Rodríguez-Baño, Jesús, de Cueto, Marina, Oliver, Antonio, de Gopegui, Enrique Ruiz, Cano, Angela, Machuca, Isabel, Gozalo-Marguello, Monica, Martinez-Martinez, Luis, Gonzalez-Barbera, Eva M., Alfaro, Iris Gomez, Salavert, Miguel, Beovic, Bojana, Saje, Andreja, Mueller–Premru, Manica, Pagani, Leonardo, Vitrat, Virginie, Kofteridis, Diamantis, Zacharioudaki, Maria, Maraki, Sofia, Weissman, Yulia, Paul, Mical, Dickstein, Yaakov, Leibovici, Leonard, and Yahav, Dafna

Published
2022
Full Text
View/download PDF

17. The clinical and microbiological efficacy of temocillin versus cefotaxime in adults with febrile urinary tract infection, and its effects on the intestinal microbiota: a randomised multicentre clinical trial in Sweden

Author

Edlund, Charlotta, Ternhag, Anders, Skoog Ståhlgren, Gunilla, Edquist, Petra, Östholm Balkhed, Åse, Athlin, Simon, Månsson, Emeli, Tempé, Maria, Bergström, Jakob, Giske, Christian G, Holmström, Daniel, Lindgren, Anna-Karin, Otto, Gisela, Furberg, Maria, Fält, Johan, Hedman, Elin, and Hanberger, Håkan

Published
2022
Full Text
View/download PDF

18. Amoxicillin-Clavulanate Breakpoints Against Enterobacterales: Rationale for Revision by the Clinical and Laboratory Standards Institute.

Author

Narayanan, Navaneeth, Mathers, Amy J, Wenzler, Eric, Moore, Nicholas M, Giske, Christian G, Mendes, Rodrigo E, and Edelstein, Paul H

Subjects
NONPROFIT organizations, ENTEROBACTERIACEAE diseases, MICROBIAL sensitivity tests, CLAVULANIC acid, ENZYME inhibitors, DRUG resistance in microorganisms, AMOXICILLIN, PATHOLOGICAL laboratories, PHARMACODYNAMICS
Abstract

Amoxicillin-clavulanate (AMC) is among the most frequently prescribed antibiotics globally. It has broad antibacterial activity against gram-positive, gram-negative, and anaerobic bacteria and has been used to treat infections caused by a broad range of pathogens. AMC breakpoints against Enterobacterales were initially set in the 1980s. However, since that time, increases in antibiotic resistance, advances in pharmacokinetic/pharmacodynamic analyses, and publication of additional clinical data prompted a reassessment by the Clinical and Laboratory Standards Institute (CLSI) Subcommittee on Antimicrobial Susceptibility Testing. Based on this contemporary reappraisal, the CLSI retained the Enterobacterales breakpoints but revised comments regarding dosing associated with use of the AMC breakpoints in the 2022 supplement of M100. This viewpoint provides insight into the CLSI breakpoint reevaluation process and summarizes the data and rationale used to support these revisions to the AMC Enterobacterales breakpoint. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

21. Treatment, outcomes and characterization of pathogens in urinary tract infections caused by esbl-producing enterobacterales : a prospective multicentre study

Author

Montelin, Hanna, Camporeale, Angela, Hallgren, Anna, Angelin, Martin, Hogvall, Jonas, Balkhed, Åse Östholm, Vading, Malin, Giske, Christian G., Tängdén, Thomas, Montelin, Hanna, Camporeale, Angela, Hallgren, Anna, Angelin, Martin, Hogvall, Jonas, Balkhed, Åse Östholm, Vading, Malin, Giske, Christian G., and Tängdén, Thomas

Abstract

Objectives: Treatment options for urinary tract infections (UTIs) caused by ESBL-producing Enterobacterales are limited. Moreover, evidence to support therapeutic decisions is lacking. This study assessed current treatment strategies and patient and pathogen characteristics in relation to clinical and microbiological outcomes. Methods: Patients with UTI caused by ESBL-producing Enterobacterales were prospectively recruited by investigators at 15 infectious disease hospital departments. Data were collected on patient characteristics, treatments, clinical and microbiological cure 10–14 days after the end of treatment, and relapse within 3 months. Bacterial isolates were subjected to MIC determination and WGS. Results: In total, 235 patients (107 febrile UTI, 128 lower UTI) caused by Escherichia coli (n= 223) and Klebsiella spp. (n= 12) were included. Clinical and microbiological cure rates were 83% and 64% in febrile UTI, and 79% and 65% in lower UTI. Great variability in treatments was observed, especially in oral therapy for febrile UTI. No difference was seen in clinical outcomes with piperacillin/tazobactam (n= 28) compared with carbapenems (n= 41). Pivmecillinam was frequently used in lower UTI (n= 62), and was also associated with high clinical cure rates when used as initial therapy (10/10) or follow-up (7/8) for febrile UTI. Recurrent infection, diabetes mellitus and urogenital disease were associated (P< 0.05) with clinical failure and relapse. In E. coli, ST131 was significantly associated with relapse, and haemolysin with microbiological failure or relapse. Conclusions: Antibiotic treatments were highly variable. Patient and pathogen factors were identified as potential determinants of disease presentation and outcomes and may prove useful to guide individualized treatment and follow-up.

Published
2024
Full Text
View/download PDF

22. Molecular characteristics, fitness, and virulence of high-risk and non-high-risk clones of carbapenemase-producing Klebsiella pneumoniae

Author

Örmälä-Tiznado, Anni-Maria, Allander, Lisa, Maatallah, Makaoui, Kabir, Muhammad Humaun, Brisse, Sylvain, Sandegren, Linus, Patpatia, Sheetal, Coorens, Maarten, Giske, Christian G., Örmälä-Tiznado, Anni-Maria, Allander, Lisa, Maatallah, Makaoui, Kabir, Muhammad Humaun, Brisse, Sylvain, Sandegren, Linus, Patpatia, Sheetal, Coorens, Maarten, and Giske, Christian G.

Abstract

Extensively drug-resistant (XDR) Klebsiella pneumoniae inflict a notable burden on healthcare worldwide. Of specific concern are strains producing carbapenem-hydrolyzing enzymes, as the therapeutic options for these strains are still very limited. Specific sequence types of K. pneumoniae have been noted for their epidemic occurrence globally, but the mechanisms behind the success of specific clones remain unclear. Herein, we have characterized 20 high-risk clones (HiRCs) and 10 non-HiRCs of XDR K. pneumoniae, exploring factors connected to the epidemiological success of some clones. Isolates were subjected to core genome multilocus sequence typing analysis to determine the clonal relationships of the isolates and subsequently characterized with regard to features known to be linked to overall bacterial fitness and virulence. The genomes were analyzed in silico for capsule types, O antigens, virulence factors, antimicrobial resistance genes, prophages, and CRISPR-Cas loci. In vitro growth experiments were conducted to retrieve proxies for absolute and relative fitness for 11 HiRC and 9 non-HiRC isolates selected based on the clonal groups they belonged to, and infections in a Galleria mellonella insect model were used to evaluate the virulence of the isolates in vivo. This study did not find evidence that virulence factors, prophages, CRISPR-Cas loci, or fitness measured in vitro alone would contribute to the global epidemiological success of specific clones of carbapenemase-producing XDR K. pneumoniae. However, this study did find the HiRC group to be more virulent than the non-HiRC group when measured in vivo in a model with G. mellonella. This suggests that the virulence and epidemiological success of certain clones of K. pneumoniae cannot be explained by individual traits investigated in this study and thus warrant further experiments in the future.

Published
2024
Full Text
View/download PDF

34. Antimicrobial susceptibilities and genomic characteristics of methicillin-resistant Staphylococcus aureus resistant to mupirocin in Stockholm, Sweden.

Author

VESTBERG, NORA, RAZAVI, MOHAMMAD, GISKE, CHRISTIAN G., and HONG FANG

Subjects
MUPIROCIN, METHICILLIN-resistant staphylococcus aureus, RIFAMPIN, WHOLE genome sequencing, MICROBIAL sensitivity tests, POINT mutation (Biology)
Abstract

The aim of this study was to investigate antimicrobial susceptibilities and genomic characteristics of mupirocin-resistant MRSA isolates in Stockholm, Sweden. In total, 44 non-duplicate mupirocin-resistant MRSA isolates detected in Stockholm during 2010-2022 were investigated. Antimicrobial susceptibility testing was performed using broth microdilution method and further tested for high-level mupirocin-resistance (MuH) and rifampicin by Etest. All isolates were subjected to whole genome sequencing. 41 isolates presented MuH with MICs =1024 mg/L whilst three isolates displayed low-level mupirocin resistance (MuL). mupA-gene was detected in all MuH isolates. Point mutations in ileS gene leading to N213D and V588F were identified in the three MuL isolates. Mutation in rpoB (H481N) was detected in a rifampicin-resistant isolate. Among the isolates, 15 multi-locus sequence types (MLST) were identified, with the four most common sequence types (ST22, ST72, ST8, and ST125) accounting for 66% of the isolates. Mupirocin-resistant MRSA in Stockholm was uncommon, with a percentage of <0.5% among MRSA cases during 2010-2022. In the present study, most mupirocin-resistant isolates were MuH and mupA-positive, predominantly linked to ST22 or ST72 isolates. MuL-resistance was associated with a point mutation in the IleS protein. A multidrug-resistant ST1-MRSA-IV strain was resistant to both mupirocin and rifampicin. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

37. Agreement between rapid antigen detection test and culture for group A streptococcus in patients recently treated for pharyngotonsillitis - a prospective observational study in primary care

Author

Rystedt, Karin, Hedin, Katarina, Tyrstrup, Mia, Skoog-Stahlgren, Gunilla, Edlund, Charlotta, Giske, Christian G., Gunnarsson, Ronny, and Sundvall, Paer-Daniel

Subjects
Allmänmedicin, General Practice, Public Health, Environmental and Occupational Health, Streptococcal pharyngotonsillitis, rapid antigen detection test, primary care
Abstract

ObjectiveThe aim was to compare rapid antigen detection test (RADT) and throat culture for group A streptococci (GAS) among patients recently treated with penicillin V for GAS pharyngotonsillitis.Design and settingThe study was a secondary analysis within a randomized controlled trial comparing 5 versus 10 days of penicillin V for GAS pharyngotonsillitis. Patients were recruited at 17 primary health care centres in Sweden.SubjectsWe included 316 patients >= 6 years of age, having 3-4 Centor criteria, a positive RADT and a positive throat culture for GAS at inclusion, and also having a RADT and throat culture for GAS taken at a follow-up visit within 21 days.Main outcome measuresRADT and conventional throat culture for GAS.ResultsThis prospective study showed 91% agreement between RADT and culture at follow-up within 21 days. Only 3/316 participants had negative RADT with a positive throat culture for GAS at follow-up, and 27/316 patients with positive RADT had a negative culture for GAS. Log rank test did not reveal any difference in the decline over time of positive tests between RADT and throat culture (p = 0.24). Agreement between RADT and throat culture for GAS at the follow-up was not associated with treatment duration, number of days from inclusion until follow-up, throat symptoms at follow-up, gender, or age.ConclusionRADT and culture for GAS agreed to a high extent also after recent penicillin V treatment. RADT for GAS means a low risk for missing the presence of GAS.

Published
2023

39. Occurrence of carbapenemase-producing Klebsiella pneumoniae and Escherichia coli in the European survey of carbapenemase-producing Enterobacteriaceae (EuSCAPE): a prospective, multinational study

Author

Koraqi, Andi, Lacej, Denada, Apfalter, Petra, Hartl, Rainer, Glupczynski, Youri, Huang, Te-Din, Strateva, Tanya, Marteva-Proevska, Yuliya, Andrasevic, Arjana Tambic, Butic, Iva, Pieridou-Bagatzouni, Despo, Maikanti-Charalampous, Panagiota, Hrabak, Jaroslav, Zemlickova, Helena, Hammerum, Anette, Jakobsen, Lotte, Ivanova, Marina, Pavelkovich, Anastasia, Jalava, Jari, Österblad, Monica, Dortet, Laurent, Vaux, Sophie, Kaase, Martin, Gatermann, Sören G., Vatopoulos, Alkiviadis, Tryfinopoulou, Kyriaki, Tóth, Ákos, Jánvári, Laura, Boo, Teck Wee, McGrath, Elaine, Carmeli, Yehuda, Adler, Amos, Pantosti, Annalisa, Monaco, Monica, Raka, Lul, Kurti, Arsim, Balode, Arta, Saule, Mara, Miciuleviciene, Jolanta, Mierauskaite, Aiste, Perrin-Weniger, Monique, Reichert, Paul, Nestorova, Nina, Debattista, Sonia, Mijovic, Gordana, Lopicic, Milena, Samuelsen, Ørjan, Haldorsen, Bjørg, Zabicka, Dorota, Literacka, Elzbieta, Caniça, Manuela, Manageiro, Vera, Kaftandzieva, Ana, Trajkovska-Dokic, Elena, Damian, Maria, Lixandru, Brandusa, Jelesic, Zora, Trudic, Anika, Niks, Milan, Schreterova, Eva, Pirs, Mateja, Cerar, Tjasa, Oteo, Jesús, Aracil, Belén, Giske, Christian, Sjöström, Karin, Gür, Deniz, Cakar, Asli, Woodford, Neil, Hopkins, Katie, Wiuff, Camilla, Brown, Derek J., Grundmann, Hajo, Glasner, Corinna, Albiger, Barbara, Aanensen, David M, Tomlinson, Chris T, Andrasević, Arjana Tambić, Cantón, Rafael, Friedrich, Alexander W, Giske, Christian G, Gniadkowski, Marek, Livermore, David M, Nordmann, Patrice, Poirel, Laurent, Rossolini, Gian M, Seifert, Harald, Walsh, Timothy, and Monnet, Dominique L

Published
2017
Full Text
View/download PDF

40. Network-based multi-omics integration reveals metabolic at-risk profile within treated HIV-infection

Author

Mikaeloff, Flora, primary, Gelpi, Marco, additional, Benfeitas, Rui, additional, Knudsen, Andreas D, additional, Vestad, Beate, additional, Høgh, Julie, additional, Hov, Johannes R, additional, Benfield, Thomas, additional, Murray, Daniel, additional, Giske, Christian G, additional, Mardinoglu, Adil, additional, Trøseid, Marius, additional, Nielsen, Susanne D, additional, and Neogi, Ujjwal, additional

Published
2023
Full Text
View/download PDF

41. Network-based multi-omics integration reveals metabolic at-risk profile within treated HIV-infection

Author

Mikaeloff, Flora, Gelpi, Marco, Benfeitas, Rui, Knudsen, Andreas D., Vestad, Beate, Hogh, Julie, Hov, Johannes R., Benfield, Thomas, Murray, Daniel, Giske, Christian G., Mardinoglu, Adil, Troseid, Marius, Nielsen, Susanne D., Neogi, Ujjwal, Hens, Niel, Mikaeloff, Flora, Gelpi, Marco, Benfeitas, Rui, Knudsen, Andreas D., Vestad, Beate, Hogh, Julie, Hov, Johannes R., Benfield, Thomas, Murray, Daniel, Giske, Christian G., Mardinoglu, Adil, Troseid, Marius, Nielsen, Susanne D., Neogi, Ujjwal, and Hens, Niel

Abstract

Multiomics technologies improve the biological understanding of health status in people living with HIV on antiretroviral therapy (PWH). Still, a systematic and in-depth characterization of metabolic risk profile during successful long-term treatment is lacking. Here, we used multi-omics (plasma lipidomic, metabolomic, and fecal 16 S microbiome) data-driven stratification and characterization to identify the metabolic at-risk profile within PWH. Through network analysis and similarity network fusion (SNF), we identified three groups of PWH (SNF-1-3): healthy (HC)-like (SNF-1), mild at-risk (SNF-3), and severe at-risk (SNF-2). The PWH in the SNF-2 (45%) had a severe at-risk metabolic profile with increased visceral adipose tissue, BMI, higher incidence of metabolic syndrome (MetS), and increased di- and triglycerides despite having higher CD4(+) T-cell counts than the other two clusters. However, the HC-like and the severe at-risk group had a similar metabolic profile differing from HIV-negative controls (HNC), with dysregulation of amino acid metabolism. At the microbiome profile, the HC-like group had a lower alpha-diversity, a lower proportion of men having sex with men (MSM) and was enriched in Bacteroides. In contrast, in at-risk groups, there was an increase in Prevotella, with a high proportion of MSM, which could potentially lead to higher systemic inflammation and increased cardiometabolic risk profile. The multi-omics integrative analysis also revealed a complex microbial interplay of the microbiome-associated metabolites in PWH. Those severely at-risk clusters may benefit from personalized medicine and lifestyle intervention to improve their dysregulated metabolic traits, aiming to achieve healthier aging., QC 20230414

Published
2023
Full Text
View/download PDF

42. Therapeutic-oligonucleotides activated by nucleases (TOUCAN) : A nanocarrier system for the specific delivery of clinical nucleoside analogues.

Author

Borsa, Baris Ata, Hernandez, Luiza I., Jiménez, Tania, Tellapragada, Chaitanya, Giske, Christian G, Hernandez, Frank J, Borsa, Baris Ata, Hernandez, Luiza I., Jiménez, Tania, Tellapragada, Chaitanya, Giske, Christian G, and Hernandez, Frank J

Abstract

Nucleoside analogues have been in clinical use since 1960s and they are still used as the first therapeutic option for several cancers and viral infections, due to their high therapeutic efficacy. However, their wide clinical acceptance has been limited due to their high toxicity and severe side effects to patients. Herein, we report on a nanocarrier system that delivers nucleosides analogues in a target-specific manner, making nucleoside-based therapeutics safer and with the possibility to be used in other human conditions. This system, named, Therapeutic OligonUCleotides Activated by Nucleases" (TOUCAN) combines: i) the recognition power of oligonucleotides as substrates, ii) the use of nucleases as enzymatic biomarkers and iii) the clinical efficacy of nucleoside analogues, in a single approach. As a proof-of-concept, we report on a TOUCAN that is activated by a specific nuclease produced by bacteria and releases a therapeutic nucleoside, floxuridine. We demonstrate, for the first time, that, by incorporating a therapeutic nucleoside analogue into oligonucleotide probes, we can specifically inhibit bacterial growth in cultures. In this study, Staphylococcus aureus was selected as the targeted bacteria and the TOUCAN strategy successfully inhibited its growth with minimal inhibitory concentration (MIC) values ranging from 0.62 to 40 mg/L across all tested strains. Moreover, our results indicate that the intravenous administration of TOUCANs at a dose of 20 mg/kg over a 24-h period is a highly effective method for treating bacterial infections in a mouse model of pyomyositis. Importantly, no signs of toxicity were observed in our in vitro and in vivo studies. This work can significantly impact the current management of bacterial infections, laying the grounds for the development of a different class of antibiotics. Furthermore, it can provide a safer delivery platform for clinical nucleoside therapeutics in any human conditions, such as cancer and viral infection, Funding: Knut and Alice Wallenberg Foundation [LiU 301097]; Swedish Research Council [2021-05641]; Swedish Research Council [2021-05641] Funding Source: Swedish Research Council

Published
2023
Full Text
View/download PDF

45. Performance of automated antimicrobial susceptibility testing for the detection of antimicrobial resistance in gram‐negative bacteria: a NordicAST study.

Author

Leegaard, Truls M., Justesen, Ulrik S., Matuschek, Erika, Giske, Christian G., Björnsdóttir, María Kristín, Suomala, Päivi, Piiparinen, Heli, Kärpänoja, Pauliina, Kauranen, Jari, Peltola, Joanna, Saha, Kerttu, Gammelsrud, Karianne Wiger, Bjørnholt, Jørgen, Mjøen, Andreas, Richter, Malgorzata, Ranheim, Trond E., Nilsen, Einar, Tomren, Heidi Aasen, Høie, Mina Ø, and Møller‐Stray, Janne

Subjects
MICROBIAL sensitivity tests, GRAM-negative bacteria, DRUG resistance in microorganisms, COLISTIN, MEROPENEM, MEDICAL microbiology, KLEBSIELLA pneumoniae, PSEUDOMONAS aeruginosa
Abstract

Automated testing of antimicrobial susceptibility is common in clinical microbiology laboratories but their ability to detect low‐level resistance has been questioned. This Nordic multicentre study aimed to evaluate the performance of commercially available automated AST systems. A phenotypically well‐characterised collection of gram‐negative bacilli (Escherichia coli (n = 7), Klebsiella pneumoniae (n = 6) and Pseudomonas aeruginosa (n = 7)) with and without resistance mechanisms was examined by Danish (n = 1), Finnish (n = 6), Norwegian (n = 16) and Swedish (n = 5) laboratories. Minimum inhibitory concentrations (MICs) were determined for 12 antimicrobials with automated systems and compared with MICs obtained with gold standard broth microdilution. The automated systems used were VITEK 2 (n = 23), Phoenix (n = 4), MicroScan (n = 1), and ARIS (n = 1). Very major errors were identified for six antimicrobials; cefotaxime (6.9%), meropenem (0.4%), ciprofloxacin (0.7%), ertapenem (4.3%), amikacin (3.4%) and colistin (6.4%). Categorical agreement of MIC for the automated systems compared to broth microdilution ranged from 83% for imipenem to 100% for ampicillin and trimethoprim‐sulfamethoxazole. The analysis revealed several important antimicrobials where resistance was underestimated, potentially with significant consequences in patient treatment. The results cast doubt on the use of automated AST in the management of patients with serious infections and suggests that more work is needed to define their limitations. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

46. Author response: Network-based multi-omics integration reveals metabolic at-risk profile within treated HIV-infection

Author

Mikaeloff, Flora, primary, Gelpi, Marco, additional, Benfeitas, Rui, additional, Knudsen, Andreas D, additional, Vestad, Beate, additional, Høgh, Julie, additional, Hov, Johannes R, additional, Benfield, Thomas, additional, Murray, Daniel, additional, Giske, Christian G, additional, Mardinoglu, Adil, additional, Trøseid, Marius, additional, Nielsen, Susanne D, additional, and Neogi, Ujjwal, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results